Drug intelligence / Profile preview

PVT-100

Development stage: Unknown
Lead developer: Pivotal Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**PVT-100** is a prescription omega-3 formulation developed by Pivotal Therapeutics for cardiovascular indications. It represents a novel therapeutic approach targeting lipid modulation, with a Phase 2a clinical trial (POMEGA) evaluating its efficacy and safety in patients, potentially expanding indications beyond standard omega-3 uses. The program received final Health Canada approval for the trial, with the first patient enrolled, focusing on outcomes that could support new prescription regimes for omega-3 therapies.[2][8]

Targets

LPCAT1 (Lysophosphatidylcholine acyltransferase 1)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on PVT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVT-100.

Explore the full profile